Sezary Monitoring Flow Cytometry, Blood
Use
Sezary Monitoring Flow Cytometry test is used to monitor the response to therapy in patients with previously diagnosed Sezary syndrome or mycosis fungoides. These are distinct but related T-cell lymphoproliferative disorders involving the skin and are commonly referred to as cutaneous T-cell lymphomas. Monitoring involves quantitative assessment of circulating neoplastic CD4-positive T-cells in peripheral blood, which is essential for disease staging and evaluating therapy response in CTCL. Flow cytometry remains the method of choice for estimating Sezary cells in peripheral blood, offering a more reproducible and timely alternative to morphological quantitation.
Special Instructions
Not provided.
Limitations
Correlation with clinical features is necessary for diagnosing Sezary syndrome, as the test analysis can only describe a cell population with aberrant phenotype and TCR beta-chain restriction, but the significance in isolation is uncertain. Gross hemolysis is a cause for specimen rejection.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 101117-0 - Sezary syndrome monitoring Bld Doc FC
- 50398-7 - Narrative diagnostic report-Imp
- 30954-2 - Relevant dx tests/lab data note
- 22635-7 - Path report.microscopic Spec Other Stn
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
6 mL
Minimum Volume
1 mL
Container
Yellow top (ACD solution A or B)
Collection Instructions
Send whole blood specimen in original tube. Do not aliquot. Label specimen as blood.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |
| Refrigerated | 4 days |